EQ

Equillium, Inc. (EQ) - 10-K Filing Summary

Business Context and Reporting Period

Company: Equillium, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Equillium is a clinical-stage biotechnology company developing novel therapies for severe autoimmune and inflammatory disorders. Its primary focus is advancing EQ504, a preclinical-stage aryl hydrocarbon receptor (AhR) modulator for ulcerative colitis (UC) and other gastrointestinal diseases. The company also holds rights to EQ302, a preclinical-stage inhibitor of IL-15 and IL-21 for celiac disease. The company has no approved products and has not generated product revenue.

Key Financial Metrics

Note: 2024 revenue was derived from an Asset Purchase Agreement with Ono Pharmaceutical Co., Ltd., which expired in October 2024. No revenue was recognized in 2025.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero in 2025 compared to $41.1 million in 2024 due to the expiration of the Ono Pharmaceutical agreement and the termination of the Biocon collaboration.
• Expense Reduction: R&D expenses decreased by $24.6 million (66%) primarily due to the wind-down of clinical studies for discontinued assets (EQ001, EQ101, EQ102) and negotiated discounts with vendors. G&A expenses decreased by $1.1 million.
• Increased Net Loss: Despite lower expenses, the net loss widened to $22.4 million from $8.1 million due to the complete loss of revenue streams.
• Capital Structure: The company significantly increased its cash position through equity financing. As of December 31, 2025, cash was $30.3 million. Subsequent to year-end, the company raised an additional $35.0 million in March 2026.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Liquidity: Management believes cash on hand (including the March 2026 financing) is sufficient to fund operations into 2029.
• Development Timeline: The company intends to commence a Phase 1 proof-of-mechanism study for EQ504 in mid-2026, with data expected approximately six months thereafter.
• Future Funding: The company expects to incur significant operating losses for the foreseeable future and will require substantial additional capital to complete development and commercialization.

Key Risks and Contingencies:

• Going Concern: The company has incurred significant losses since inception and has an accumulated deficit of $216.2 million. Continued losses are expected.
• Regulatory Approval: Success depends entirely on the successful development and regulatory approval of EQ504 and EQ302, which are currently preclinical.
• Financing Risk: Failure to raise additional capital could force the company to delay, reduce, or eliminate R&D programs.
• Third-Party Reliance: The company relies on Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) for all manufacturing and clinical studies.
• Cryptocurrency Strategy: The company announced a treasury strategy to potentially invest in digital currencies, introducing volatility risks to its financial results.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $65.3 million total cash position (year-end + March 2026 proceeds) against the projected burn rate to reach the mid-2026 Phase 1 milestone.
• EQ504 Preclinical Data: Review the specific preclinical data supporting the decision to advance EQ504 to Phase 1, particularly regarding safety and efficacy in UC models.
• Financing Terms: Examine the terms of the August 2025 and March 2026 private placements, specifically the dilution impact of pre-funded warrants and the conditions for the potential second closing of the August deal.
• Patent Portfolio: Confirm the status and expiration dates of the patent families acquired from Ariagen (EQ504) and Bioniz (EQ302).
• Cryptocurrency Exposure: Monitor any future disclosures regarding the actual implementation of the cryptocurrency treasury strategy and its impact on the balance sheet.